Switzerland · Delayed Price · Currency is CHF Straumann Holding AG Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 7.1% organic revenue growth, led by strong gains in Latin America, EMEA, and North America, with robust innovation and digital adoption driving market share. Margin guidance is reaffirmed despite FX headwinds and China VBP uncertainty, supported by operational efficiencies.
Fiscal Year 2025
-
Revenue grew 8.9% organically to CHF 2.6 billion in 2025, with strong EBIT margin and cash flow despite currency and tariff headwinds. Innovation, digitalization, and regional expansion drove growth, while 2026 guidance anticipates high single-digit organic growth and margin improvement.
-
Aiming for 10% CAGR revenue and 40–50 bps EBIT margin growth (2026–2030), the group leverages innovation, digitalization, and a multi-brand strategy to expand in under-penetrated dental markets. Transformation in ortho and digital, cost efficiencies, and local manufacturing underpin profitability, while FX and regulatory risks are actively managed.
-
Q3 saw 8.3% organic revenue growth, led by EMEA and Latin America, with strong innovation and strategic partnerships in orthodontics and digital. Despite headwinds in China and tariffs, full-year guidance for high single-digit growth and margin improvement is confirmed.
-
Revenue grew 10.2% organically in H1 2025, with strong regional performance and robust gross margins despite FX and tariff headwinds. iEXCEL implants and digital innovations are driving market share gains, and guidance for high single-digit growth and margin improvement is reaffirmed.
-
Q1 2025 saw 11% organic revenue growth to CHF 681 million, led by strong EMEA and APAC performance, new product launches, and digital solutions. Guidance for 2025 remains high single-digit growth with EBIT margin improvement, despite macro and FX headwinds.
Fiscal Year 2024
-
Strong organic revenue growth of 13.7% to CHF 2.5 billion was achieved in 2024, with robust market share gains, especially in implantology and Asia-Pacific. Investments in innovation, digitalization, and capacity expansion support a positive outlook for high single-digit growth and margin improvement in 2025.
-
Q3 saw 11.2% organic revenue growth, with EMEA and APAC regions leading double-digit gains, while North America faced macro headwinds but gained market share. New product launches and manufacturing investments support a confident outlook for low double-digit growth and 27%-28% profitability in 2024.
-
Revenue grew 16.1% organically in H1 2024, with strong EBIT margin and robust growth across all regions, especially Asia Pacific. Updated 2024 guidance calls for low double-digit organic growth and 27%-28% profitability, reflecting both the DrSmile divestiture and strong core business momentum.